Journal article
Underutilisation of breast cancer prevention medication in Australia
C Macdonald, JA Chamberlain, D Mazza, RL Milne, KA Phillips
Breast | CHURCHILL LIVINGSTONE | Published : 2021
Abstract
Increased implementation of proven prevention strategies is required to combat rising breast cancer incidence. We assessed use of risk reducing medication (RRMed) by Australian women at elevated breast cancer risk. Only 2.4% had ever used RRMed. Higher breast cancer risk was statistically significantly associated with use of RRMed (OR 1.82, 95%CI: 1.08–3.07, p = 0.02 for ≥30% lifetime risk compared with 16%–29% lifetime risk), but parity, education level and family history of breast cancer were not. Breast cancer prevention medications are underutilised. Efforts are needed to incorporate breast cancer risk assessment and risk management discussions into routine health assessments for women.
Related Projects (3)
Grants
Awarded by National Institutes of Health
Funding Acknowledgements
This research was supported by Cancer Australia and the National Breast Cancer Foundation (PdCCRS #1100868). kConFab and the kConFab Follow-Up Study have received additional funding support from Cancer Australia (809195), the Australian National Breast Cancer Foundation (IF 17), the Australian National Health and Medical Research Council (454508, 288704, 145684), the National Institute of Health U.S.A. (1RO1CA159868), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. KAP is an Australian National Health and Medical Research Council Leadership Fellow. The contents of this manuscript are solely the responsibility of the authors and do not necessarily reflect the views of Cancer Australia.